Correction: J Exp Clin Cancer Res 40, 320 (2021)
https://doi.org/10.1186/s13046-021-02127-x
Following publication of the original article [1], the authors identified an error in Fig. 6. The image representative of cell nuclei (DAPI staining) of the group “control” (panel “b”, first on the left) was unintentionally duplicated in panel “c” relative to the group “oxaliplatin” during the image assembly process by the authors.
The correction does not alter the scientific outcome since the result about the colocalization analysis of VEGF-A and GFAP in control and oxaliplatin-treated mice did not require the use of DAPI channel. The original article [1] has been corrected.
Incorrect Fig. 6
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
Correct Fig. 6
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
Reference
Micheli L, Parisio C, Lucarini E, et al. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res. 2021;40:320. https://doi.org/10.1186/s13046-021-02127-x.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Micheli, L., Parisio, C., Lucarini, E. et al. Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res 43, 120 (2024). https://doi.org/10.1186/s13046-024-03037-4
Published:
DOI: https://doi.org/10.1186/s13046-024-03037-4